Skip to main content

Table 5 Safety and treatment exposure according to age

From: Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Parameter

< 70 years (n = 41)

≥ 70 years (n = 10)

Any grade TEAE

35 (85%)

9 (90%)

Grade ≥ 3 TEAE

14 (34%)

5 (50%)

Dose interruptions *

  

Yes

23 (56%)

7 (78%)

No

18 (44%)

2 (22%)

Dose reduction *

  

Yes

18 (44%)

7 (78%)

No

23 (56%)

2 (22%)

Reason for discontinuation

  

Progression

32 (78%)

6 (60%)

Toxicity

3 (7%)

2 (20%)

Others

3 (7%)

0

On treatment

3 (7%)

2 (20%)

  1. Data are n (%). *1 patient aged > 70 years was excluded from the analysis as the recommended dose modification scheme was not followed. †Doctor’s or patient’s decision.